C.M. Bidwell & Associates’s Myriad Genetics MYGN Stock Holding History

C.M. Bidwell & Associates’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-105	Closed	-$646	–	510
2025 Q4	$646	Buy	+105	New	+$761	﹤0.01%	454
2018 Q4	–	Sell	-4,425	Closed	-$204K	–	439
2018 Q3	$204K	Buy	4,425 +1,645	+59%	+$73.1K	0.19%	134
2018 Q2	$104K	Buy	+2,780	New	+$93.9K	0.1%	180
2016 Q2	–	Sell	-3,950	Closed	-$148K	–	291
2016 Q1	$148K	Buy	+3,950	New	+$149K	0.04%	203
2014 Q4	–	Sell	-8,425	Closed	-$325K	–	234
2014 Q3	$325K	Hold	8,425	–	–	0.08%	111
2014 Q2	$328K	Hold	8,425	–	–	0.07%	108
2014 Q1	$288K	Buy	+8,425	New	+$261K	0.07%	117
2013 Q4	–	Sell	-88,520	Closed	-$2.08M	–	240
2013 Q3	$2.08M	Sell	88,520 -505	-0.6%	-$14.3K	0.57%	86
2013 Q2	$2.39M	Buy	+89,025	New	+$2.58M	0.7%	75

Other funds holding MYGN

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

C.M. Bidwell & Associates's MYGN Position: Q1 2026 in Review

C.M. Bidwell & Associates sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 105 shares — an estimated $646 sold.

C.M. Bidwell & Associates first reported a position in MYGN in Q2 2013 and held it in 9 quarters. The position peaked at $2.39M in Q2 2013. 203 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

C.M. Bidwell & Associates reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
C.M. Bidwell & Associates sold 105 Myriad Genetics shares in Q1 2026, an estimated $646.
C.M. Bidwell & Associates first reported a position in Myriad Genetics in Q2 2013 and held it in 9 quarters.
C.M. Bidwell & Associates's Myriad Genetics position peaked at $2.39M in Q2 2013.
203 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.